Trial Profile

A study of bioequivalence between HD201 and trastuzumab sourced in the European Union (EU-trastuzumab)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary)
Indications Breast cancer; Gastric cancer; Oesophageal cancer
Focus First in man; Pharmacokinetics

Most Recent Events

31 May 2019 Results assessing analytical biocomparability physiochemical and biological properties between HD201 and EU and US-Herceptin in terms published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
08 Mar 2018 New trial record
01 Mar 2018 Primary endpoint (AUC0-infinity) has been met as per the results published in the Clinical Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com